SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. Its lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. Show more
Location: 31 East 62nd Street, New York, NY, 10065, United States | Website: https://www.siga.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
616.5M
52 Wk Range
$4.95 - $9.62
Previous Close
$8.61
Open
$8.55
Volume
545,020
Day Range
$8.34 - $8.58
Enterprise Value
434.3M
Cash
182.5M
Avg Qtr Burn
N/A
Insider Ownership
43.24%
Institutional Own.
50.20%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TPOXX (Intravenous) Details Smallpox, Vaccine | Approved Update | |
TPOXX® (tecovirimat) Details Smallpox | Approved Quarterly sales |